24.12.2012 Views

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

Annual Meeting Proceedings Part 1 - American Society of Clinical ...

SHOW MORE
SHOW LESS

You also want an ePaper? Increase the reach of your titles

YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.

136s Central Nervous System Tumors<br />

2085 General Poster Session (Board #17H), Sat, 1:15 PM-5:15 PM<br />

The role <strong>of</strong> fluorescence-guided surgical resection in the combined treatment<br />

<strong>of</strong> malignant glioma. Presenting Author: Carmine Maria Carapella,<br />

Neurosurgery, Cancer Institute Regina Elena, Roma, Italy<br />

Background: Malignant glioma represents a relevant therapeutic issue and<br />

the value <strong>of</strong> extensive surgical resection remains debated; recent evidence<br />

suggests that radical removal is associated with better survival. An<br />

interesting tool for identifying tumor tissue and increasing the extent <strong>of</strong><br />

surgery is represented by fluorescence-guided resection, taking advantage<br />

<strong>of</strong> metabolic and structural changes induced by a natural precursor <strong>of</strong> heme<br />

biosynthetic pathway, 5-amino-levulinic acid (ALA). Methods: The present<br />

experience is related to 32 patients affected by malignant glioma (18 newly<br />

diagnosed: 16 glioblastoma (GBM), 2 anaplastic oligodendroglioma; and<br />

14 recurrent GBM) eligible for fluorescence-guided resection, operated on<br />

in our Institute since fall <strong>of</strong> 2009. All patients underwent preoperative and<br />

early postoperative MRI, showing contrast enhancing lesions. An oral dose<br />

<strong>of</strong> 20 mg 5-ALA /kg bw was administered to each patient. Microsurgical<br />

resection was performed by an operating microscope enabled to visualize<br />

the fluorescence. All the patients, as first line treatment, have been<br />

submitted to radiotherapy and chemotherapy; second and in some cases<br />

third line treatments were utilized in recurrent cases. The patients<br />

follow-up ranged from 2 years to 6 months. Results: In more than 90% <strong>of</strong><br />

patients tumor tissue showed intraoperative red fluorescence; mainly in<br />

recurrent GBM, when MRI documented heterogeneous lesions with enhancing<br />

areas mixed with non enhancing gliotic scars, fluorescence-guided<br />

surgery allowed a better definition <strong>of</strong> active tumor, with net margins from<br />

perilesional “healthy” brain. Early postoperative MRI confirmed gross total<br />

resection without contrast enhancement in 80 % <strong>of</strong> patients. In the present<br />

experience the procedure did not determine any relevant additional<br />

neurological deficit. Considering overall survival <strong>of</strong> recurrent patients we<br />

obtained a median extension <strong>of</strong> at least 9.0 months (3 – 16� months).<br />

Conclusions: Fluorescence-guided surgery improves tumor detection and<br />

allows extended resection <strong>of</strong> malignant glioma, without any relevant impact<br />

on neurological status, resulting helpful mainly in the recurrent setting with<br />

a consistent effect on overall survival.<br />

2087 General Poster Session (Board #18B), Sat, 1:15 PM-5:15 PM<br />

Correlation <strong>of</strong> survival with tumor antigen expression in patients with newly<br />

diagnosed glioblastoma receiving a multi-epitope pulsed dendritic cell<br />

vaccine. Presenting Author: Surasak Phuphanich, Neuro-Oncology Program,<br />

Cedars-Sinai Medical Center, Los Angeles, CA<br />

Background: This study evaluated the safety and immune responses to an<br />

autologous dendritic cell vaccine pulsed with class I peptides from tumor<br />

associated antigens (TAA) expressed on gliomas and overexpressed in their<br />

cancer stem cell population (ICT-107). These TAA epitodes AIM-2. TRP-2,<br />

HER2 and AIM-2, are also overexpressed on glioblastoma multiforme<br />

(GBM) cancer stem cells. Methods: TAA epitopes included HER2, TRP-2,<br />

gp100, MAGE-1, IL13R�2, and AIM-2. HLA-A1 and/or HLA-A2 positive<br />

glioblastoma (GBM) patients with gross total resection were eligible.<br />

Mononuclear cells from leukapheresis were differentiated into dendritic<br />

cells, pulsed with TAA peptides, and administered intradermally three<br />

times at two-week intervals in the axilla region after a standard treatment<br />

with concurrent temozolomide (TMZ) and radiation therapy for newly<br />

diagnosed (ND-GBM). Results: Twenty-one patients were enrolled with 17<br />

ND-GBM and three recurrent GBM patients and one brainstem glioma.<br />

Immune response data on 15 newly diagnosed patients showed 33%<br />

responders. TAA expression by qRT-PCR showed all patient tumors<br />

expressed at least three TAA with 75% expressing all six. Correlations <strong>of</strong><br />

increased PFS and quantitative expression <strong>of</strong> MAGE1, AIM-2, gp100 and<br />

HER2 were observed. A decrease or absence <strong>of</strong> CD133 expression was seen<br />

in five patients who underwent a second resection. As <strong>of</strong> February 1, 2012,<br />

six <strong>of</strong> 16 ND-GBM patients showed no evidence <strong>of</strong> tumor recurrence<br />

(44-63 months). Median progressive free survival (PFS) in newly diagnosed<br />

patients was 16.9 months with a two-year PFS rate was 43.8%<br />

(95%CI,19.8-66.0 ). The median overall survival rate (OS) was 38.4<br />

months and a two-year OS was 80.3% (95%CI,58.6-96.7). Conclusions:<br />

Expression <strong>of</strong> four ICT-107 targeted antigens in the pre-vaccine tumors<br />

correlated with prolonged overall survival and PFS in ND-GBM patients.<br />

The goal <strong>of</strong> targeting tumor antigens highly expressed on glioblastoma<br />

cancer stem cells is supported by the observation <strong>of</strong> decreased or absent<br />

CD133 expression in the recurrent areas <strong>of</strong> gadolinium-enhanced tumor.<br />

2086 General Poster Session (Board #18A), Sat, 1:15 PM-5:15 PM<br />

An investigator-initiated monocentric phase I dose escalation trial <strong>of</strong><br />

temsirolimus and irinotecan (TEMIR) in patients with relapsing glioblastoma<br />

multiforme (reGBM). Presenting Author: Max E. Scheulen, Department<br />

<strong>of</strong> Medical Oncology, West German Cancer Center, University <strong>of</strong><br />

Duisburg-Essen, University Hospital Essen, Essen, Germany<br />

Background: Deregulation <strong>of</strong> the PI3K/AKT pathway has been preclinically<br />

involved in the pathophysiology <strong>of</strong> GBM. The mammalian target <strong>of</strong><br />

rapamycin (mTOR) is an important downstream mediator <strong>of</strong> PI3K/AKT<br />

signalling. The mTOR-inhibitor temsirolimus (Tem) achieves significant<br />

drug levels in brain. Thus, Tem may be effectively combined with irinotecan<br />

(Iri) which has shown promising results in combination with bevacizumab<br />

in patients (pts) with reGBM refractory to temozolomide (Tmz) in phase II.<br />

Exposure to Tem as well as Iri is substantially reduced in pts receiving<br />

CYP3A4 enzyme-inducing anticonvulsants (CYP3A4-Ind). Methods: TEMIR<br />

is a phase I trial <strong>of</strong> escalating doses <strong>of</strong> Tem in combination with Iri in pts<br />

with reGBM refractory to Tmz depending on the cotreatment with CYP3A4-<br />

Ind. In pts without CYP3A4-Ind dose escalation <strong>of</strong> Tem was performed<br />

according to the “3�3 protocol” from 15 via 20 to 25 mg iv wkly together<br />

with 85 mg/m2 Iri iv wkly. In pts with CYP3A4-Ind the doses <strong>of</strong> Tem were<br />

30, 40 and 50 mg iv wkly together with 170 mg/m2 Iri iv wkly, respectively.<br />

The determination <strong>of</strong> the pharmacokinetics (PK) <strong>of</strong> Tem and its influence<br />

on the PK <strong>of</strong> Iri and its active metabolite SN38 was performed by validated<br />

RP-HPLC methods with fluorescence detection. Results: Up to now, 14 pts<br />

[4 female and 10 male, median age 47 yrs (range 41-65 yrs), 9 without and<br />

5 with CYP3A4-Ind] have been treated. All 9 pts without CYP3A4-Ind (3<br />

pts on 15, 20 and 25 mg Tem each) are evaluable for safety with only mild<br />

toxicity [highest CTC-grade �2 (gr) per pt]: diarrhea 4 (gr2) and 1 (gr3),<br />

neutropenia 1 (gr3), thrombopenia 1 (gr2), anemia 1 (gr2), pneumonia 2<br />

(gr2), rash 1 (gr2). PK parameters <strong>of</strong> Iri and SN38 were in agreement with<br />

previously published studies and there was no significant effect <strong>of</strong> 15 to 25<br />

mg Tem combined with 85 mg/m2 Iri on the PK <strong>of</strong> Iri and SN38. In 7 pts<br />

evaluable for efficacy there was no remission (RECIST) and median time to<br />

symptomatic and/or MRT progression was 10 wks (7, 9�, 10, 10�, 11,<br />

15, 20 wks). Conclusions: The combination <strong>of</strong> Tem in standard dose <strong>of</strong> 25<br />

mg iv wkly with 85 mg/m2 Iri wkly is safe in pts with reGBM without<br />

CYP3A4-Ind. Tem has no significant effect on the PK <strong>of</strong> Iri and SN38.<br />

2089 General Poster Session (Board #18D), Sat, 1:15 PM-5:15 PM<br />

High-dose chemotherapy (HDC) followed by autologous stem cell transplant<br />

(ASCT) for recurrent/progressive CNS lymphoma. Presenting Author:<br />

Mary Roberta Welch, Memorial Sloan-Kettering Cancer Center, New York,<br />

NY<br />

Background: In two reports by Soussain et al, promising efficacy was<br />

observed in recurrent primary CNS lymphoma with induction cytarabine/<br />

VP-16 (CYVE) followed by HDC-ASCT (busulfan, thiotepa and cyclophosphamide<br />

[BTC]), but significant toxicity, mainly from CYVE, has limited<br />

widespread use. We report our experience with HDC-ASCT with alternative<br />

induction regimens. Methods: Retrospective review <strong>of</strong> pts with recurrent/<br />

refractory non-Hodgkin lymphoma (NHL) with CNS involvement treated<br />

with HDC-ASCT (2000-present). Results: Seventeen pts met inclusion<br />

criteria: med age� 58 (41-65); 9 were women; med KPS prior to<br />

transplant� 90 (range 70-100). At initial presentation, 10 had primary<br />

CNS lymphoma (ocular: 1); 7 had systemic NHL without CNS involvement;<br />

1 had both systemic and CNS disease. Pts had been heavily pre-treated.<br />

Among those with PCNSL, high dose MTX was used in all pts and WBRT in<br />

4. Two pts had received a previous HDC-ASCT. Among systemic NHL pts,<br />

various regimens were used, mostly R-CHOP(4), but also R-EPOCH (1),<br />

CVP (1), ICE (1) and CODOX-M (1). At CNS recurrence, pts received various<br />

induction regimens prior to HD-ASCT: high-dose methotrexate (MTX)based<br />

chemotherapy (N� 13), cytarabine-based regimens (N�2), and<br />

other (N� 2). All pts achieved a CR or near CR prior to HDC-ASCT.<br />

Harvesting was obtained with G-CSF alone in 9 pts; 8 required plerixafor.<br />

Two pts failed mobilization N�15 received HDC-ASCT. The HDC consisted<br />

<strong>of</strong> BTC (N�13); 1 received BEAM and 1 received reduced intensity<br />

fludarabine, melphalan and alemtuzumab. Eight pts experienced a grade<br />

III or IV toxicity – most commonly fatigue, febrile neutropenia, and<br />

infection. One previously transplanted pt died from sepsis. With a med<br />

follow-up <strong>of</strong> 11 months, post-transplant med-PFS has not been reached.<br />

The 12m PFS was 92% (95% CI 56-98). Because no patient has<br />

progressed, the OS was identical to PFS. Conclusions: HDC-ASCT was a<br />

highly effective salvage approach in this population <strong>of</strong> recurrent/refractory<br />

CNS lymphoma. To reduce the risk <strong>of</strong> harvesting failure at the time <strong>of</strong><br />

recurrence, harvesting stem cells at the time <strong>of</strong> initial treatment could be<br />

considered in pts with high risk for relapse.<br />

Visit abstract.asco.org and search by abstract for the full list <strong>of</strong> abstract authors and their disclosure information.

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!